What is Maxygen?
Maxygen, a prominent biotech entity situated in the San Francisco Bay Area, is at the forefront of directed evolution and molecular breeding technology. The company excels in generating diverse genetic libraries rich in functional content, providing an economical pathway for directed evolution screening campaigns. Maxygen offers specialized molecular biology services, including DNA synthesis and advanced cloning techniques, to support partner project development without retaining ownership of intellectual property or outcomes. Their pioneering methodologies are instrumental in enhancing protein functionality across a broad spectrum of biotechnological applications.
How much funding has Maxygen raised?
Maxygen has raised a total of $96K across 1 funding round:
Debt
$96K
Debt (2021): $96K with participation from PPP
Key Investors in Maxygen
PPP
Public-Private Partnership
What's next for Maxygen?
Operating at a significant Series B/C stage, Maxygen's recent influx of substantial expansion capital is poised to accelerate its strategic objectives. This financing is expected to fuel further research and development, enhance its technological platforms, and potentially expand its market reach. The company's focus on cost-effective solutions for directed evolution screening and its comprehensive molecular biology services position it for continued leadership and innovation within the competitive biotechnology landscape.
See full Maxygen company page
